All the Drug Class Drugs
GLP-1 Receptor Agonist. Dulaglutide 0.75 mg, 1.5 mg. PRE-FILL. SYR.: 4× 0.5 ml (sol.). Monother.: 0.75 mg once wkly. Add-on ther.: 1.5 mg once wkly. For potent. vulnerable populat., such as patients ≥ 75 yrs., 0.75 mg once wkly. can be consid. as a init. dose. When added to exist. metformin and/or pioglitazone ther., the current dose of metformin and/or pioglitazone can be cont.. When it is added to exist. ther. of a sulphonylurea/ prandial insulin, a reduct. in the dose of sulphonylurea or
insulin may be consid. to reduce the risk of hypoglycaemia. See lit.
Indicated in adults with type 2 diab. mell. to improve glycaemic control as: Monother.: When diet& exercise alone do not provide adeq. glycaem. control in pts. for whom the use of metformin is consid.
inappropr. due to intoler. or contraind. Add-on therapy: In comb. with other glucose-low. med. products includ. insulin, when these, together with diet and exercise, do not provide adequate
GLP-1 Receptor Agonist. Liraglutide 6 mg/ml. PRE-FILLED PEN (sol. for inject): 30 doses
of 0.6 mg, 15 doses of 1.2 mg, or 10
doses of 1.8 mg. Initial: 0.6 mg S.C. 1 x dly for 1 wk, then incr. to 1.2 mg S.C. 1
x dly for at least 1 wk. Max dose 1.8 mg
S.C. 1 x dly.
Tmt. adults with type 2 diabetes mellitus
to achieve glycem. control. In comb.
with: Metformin or sulphonylurea, in pts
with insuff. glycem. control despite max.
tolerat. dose of monother. with
metformin or sulphonylurea; In
combinat. with metformin and a
sulphonylurea/thiazolidinedione in pts
with insuff. glycem. control despite dual